General Information of Drug (ID: DR1544)
Drug Name
Telithromycin
Synonyms
Telithromycin; Tox21_111454; Tox21_112203; KI8H7H19WL; Levviax; RU 66647; RU-66647; RU66647; SCHEMBL5100; ZINC9574770; 191114-48-4; AC1MHE79; BDBM50378137; CAS-191114-48-4; CHEBI:29688; CHEMBL1136; CS-2812; DB00976; DSSTox_CID_26455; DSSTox_GSID_46455; DSSTox_RID_81629; DTXSID3046455; HMR 3647; HMR-3647; HMR3647; HMR3647;RU66647; HY-A0062; Ketek; NCGC00164575-01; UNII-KI8H7H19WL
Indication Bronchitis [ICD11: CA20] Approved [1]
Structure
3D MOL is unavailable 2D MOL
Pharmaceutical Properties Molecular Weight 812 Topological Polar Surface Area 172
Heavy Atom Count 58 Rotatable Bond Count 11
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 13
Cross-matching ID
PubChem CID
3002190
PubChem SID
633047 ; 12015022 ; 14767066 ; 14913885 ; 17181612 ; 34667812 ; 57410165 ; 79644204 ; 103323138 ; 111611540 ; 124766275 ; 126669903 ; 134224303 ; 135253289 ; 135692562 ; 139962352 ; 140277637 ; 141465063 ; 144205007 ; 144205756 ; 152198790 ; 160857220 ; 164765238 ; 175268627 ; 179150119 ; 210279153 ; 210281475 ; 223393880 ; 226396929 ; 247267318 ; 252401574
ChEBI ID
CHEBI:29688
CAS Number
191114-48-4
TTD Drug ID
D09HNR
Formula
C43H65N5O10
Canonical SMILES
CCC1C2(C(C(C(=O)C(CC(C(C(C(=O)C(C(=O)O1)C)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C
InChI
1S/C43H65N5O10/c1-12-33-43(8)37(48(41(53)58-43)19-14-13-18-47-23-31(45-24-47)30-16-15-17-44-22-30)27(4)34(49)25(2)21-42(7,54-11)38(28(5)35(50)29(6)39(52)56-33)57-40-36(51)32(46(9)10)20-26(3)55-40/h15-17,22-29,32-33,36-38,40,51H,12-14,18-21H2,1-11H3/t25-,26-,27+,28+,29-,32+,33-,36-,37-,38-,40+,42-,43-/m1/s1
InChIKey
LJVAJPDWBABPEJ-PNUFFHFMSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
RU 72365 DM000479
11061754
Oxidation - Demethylation 1 [4] , [3]
RU 76363 DM000473
156596458
Hydrolysis - Hydrolysis 1 [4]
RU 76584 DM000480
156613685
Oxidation - Oxidation 1 [4] , [3]
Telithromycin metabolite M10b DM000475 N. A. Oxidation - Deamination 1 [4]
Telithromycin metabolite M11b DM000478 N. A. Oxidation - Deamination 1 [4]
RU 78849 DM000474 N. A. Oxidation - Oxidation 2 [4]
Telithromycin metabolite M13 DM000477 N. A. Unclear 2 [4]
Telithromycin metabolite M4'b DM000476 N. A. Unclear 2 [4]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR002370 Telithromycin RU 76363 Hydrolysis - Hydrolysis Unclear [4]
MR002371 Telithromycin Telithromycin metabolite M10b Oxidation - Deamination CYP [4]
MR002372 Telithromycin Telithromycin metabolite M11b Oxidation - Deamination CYP [4]
MR002373 Telithromycin RU 72365 Oxidation - Demethylation CYP3A4 [4], [3]
MR002374 Telithromycin RU 76584 Oxidation - Oxidation CYP3A4 ... [4], [3]
MR002365 RU 76363 RU 78849 Oxidation - Oxidation Unclear [4]
MR002366 Telithromycin metabolite M10b Telithromycin metabolite M4'b Unclear CYP [4]
MR002367 Telithromycin metabolite M10b Telithromycin metabolite M13 Unclear CYP [4]
MR002368 Telithromycin metabolite M11b Telithromycin metabolite M4'b Unclear CYP [4]
MR002369 Telithromycin metabolite M11b Telithromycin metabolite M13 Unclear CYP [4]
⏷ Show the Full List of 10 MR(s)
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[2]
Cytochrome P450 3A5 (CYP3A5) DME0012 Homo sapiens
CP3A5_HUMAN
1.14.14.1
[3]
References
1 Telithromycin was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
2 Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother. 2006 Apr;7(6):639-51.
3 Verapamil toxicity resulting from a probable interaction with telithromycin. Ann Pharmacother. 2005 Feb;39(2):357-60.
4 Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin Pharmacokinet. 2005;44(9):915-34.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.